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Abstract
The Gambia Hepatitis Intervention Study (GHIS) consisted in the progressive introduction of HBV plasma-derived
vaccine in different zones of this African country during the period 1986-1990. The study was launched and
coordinated by IARC and is one of the most effective examples of an intervention project that both substantially
contributed to our knowledge and to the health of local populations. Similar intervention studies have been
carried out in South-East Asia. The studies indicate that the natural history of HBV infection differs in different
populations , having a direct relevance for the implementation of HBV vaccination programmes in various parts of
the world.
Article
Recent estimations provided by GloboCa 2008 [1] indi-
cate that in 2008 12.7 million new cancer cases and 7.6
million cancer deaths occurred in the world and that
most of these cancers are present in developing coun-
tries either in terms of incidence (56%) or mortality
(63%). It is also expected that by 2030 some 21.4 million
new cancer cases will be diagnosed and over 13.2 mil-
lion cancer deaths will occur annually. It is estimated
that liver cancer (mostly hepatocellular carcinoma
[HCC]) is responsible for more that 600,000 cancer
deaths worldwide and represents the third most fre-
quent cause of cancer deaths [2,3]. The major causes of
hepatocellular carcinoma have been known since several
decades and in the developing countries these are HBV,
HCV infections and exposure to aflatoxins through the
diet [4-6]. Since the early 1980s an efficient and safe
vaccine against HBV infection has been available and
various intervention studies, namely in Quidong Pro-
vince, China [7], Taiwan [see 8], and The Gambia [9],
have been initiated to assess the efficacy of HBV vacci-
nation at infancy in the prevention of HCC.
All the children vaccinated within the Gambia Hepati-
tis Intervention Study (GHIS) were registered, resulting
in two cohorts of approximately 60,000 children, one of
which received only the routine EPI vaccination and the
other the HBV vaccine in addition. To determine the
response to HBV vaccine and the persistence of vac-
cine-induced immunity, some 1000 children were
recruited consecutively and these have been followed
annually to assess their HBV serological status. A cross-
sectional survey was carried out at the ages of 4 and 9
years of a similar number of unvaccinated children to
determine the vaccine efficacy against HBV carriage sta-
tus and infection.
The vaccine efficacy shows an 84% protection against
infection and 94% against HBV chronic carriage at 9
years of age (See Table 1). The evaluation of the
expected protection against the development of HCC is
expected from the year 2017 [10]. Similar intervention
studies have been carried out in South-East Asia see
[7,11]. It is of interest to note that, in the Chinese popu-
lation, perinatal transmission from mothers positive for
HBVe antigen is frequent, whereas in Africa horizontal
transmission (sibling-to-sibling) is prevalent. The study
in Taiwan shows that the incidence rate of HCC in chil-
dren of 6-19 years of age was considerably lower in chil-
dren born after the initiation of the HBV vaccination
and that this decrease was not present in children born
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[11]. These studies in Africa and South-East Asia indi-
cate that the natural history of HBV infection differs in
these populations and they have a direct relevance in
the implementation of HBVvaccination strategy.
It has been estimated that, in a surviving birth cohort
for the year 2000, routine infant HBV vaccination, with
a 90% coverage and the first dose administered at birth,
would prevent 84% of global HBV related deaths, i.e. 1.4
million [12].
In The Gambia the high incidence of HCC is also
associated with exposure to the carcinogen aflatoxin B1
through the consumption of groundnuts and maize con-
taminated with the fungi Aspergillus flavus and parasiti-
cum [6]. Comprehensive studies have been carried out
in this country to assess the relative contribution and
the interaction of the different risk factors, namely HBV
infection and aflatoxin B1, in the etiopathogenesis of
HCC [13,14]. These case-control studies, using serologi-
cal markers of exposure to HBV and aflatoxin B1 (as
determined by the presence of aflatoxin-albumin adduct
and of 249
ser p53 mutation in sera DNA), clearly show
that exposure to aflatoxins affects the entire population
and that exposure to both HBV infection and aflatoxins
results in a prominent increase risk of developing HCC.
In summary, these studies show that HBV vaccination
programmes have been successfully implemented in var-
ious parts of the world. In addition, molecular epidemio-
logical studies in The Gambia and in South-East Asia
have clearly shown the relevance of other major risk fac-
tors, namely aflatoxin exposure [see 15], in the etio-
pathogenesis of HCC.
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Table 1 Hepatitis B vaccination trials
Location
No. of
subjects
Year of recruitment/ year of Follow
up
Prevalence HBsAg
Non-vaccinated/ vaccinated
population
Efficacy Relative Risk of developing HCC
Non-vaccinated/ vaccinated
population
The Gambia*
>60000
1986-1990/ 9 yrs 10% > 1% 94% Expected 2017
China*
(Qidong)
>38000
1984-1990/ 11 yrs 7,1% > 1.66% 75% Expected >2015
Taiwan
♦ 1984 9.8% in 1984 > 0.7% in 1999 84% 0.31
■
*HBV vaccination trials programme [16,7].
♦Universal vaccination programme [11].
■64 HCC among vaccinees in 37709304 person-years versus 444 HCC in unvaccinated subjects in 78496406 person-years [11].
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